Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions

Cancer Prevention Research

Volumn 6, Issue 7, 2013, Pages 666-674

  Broussard, Elizabeth K ^a   Kim, Rachel ^a   Wiley, Jesse C ^a   Marquez, Juan Pablo ^a   Annis, James E ^a   Pritchard, David ^a   Disis, Mary L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; CADHERIN; CDH3 PROTEIN, HUMAN; CLAUDIN 1; CLDN1 PROTEIN, HUMAN; KERATIN TYPE I; KRT23 PROTEIN, HUMAN; MATRILYSIN; MESSENGER RNA; MMP7 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR MARKER;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PREVENTION; CDH3 GENE; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOMAL INSTABILITY; CLDN1 GENE; CLINICAL ARTICLE; COLON ADENOMA; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE; GENE CONTROL; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; KRT23 GENE; MALE; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; MMP7 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ADENOMA; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CASE CONTROL STUDY; CHEMISTRY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DNA METHYLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CADHERINS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CLAUDIN-1; COLORECTAL NEOPLASMS; DNA METHYLATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATINS, TYPE I; MALE; MATRIX METALLOPROTEINASE 7; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84880080335     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0484     Document Type: Article

References (53)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
2. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
3. BertagnolliMM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
4. Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, et al. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst 2009;101:267-76.
5. Burn J, Bishop DT, Chapman PD, Elliott F, Bertario L, Dunlop MG, et al. A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis. Cancer Prev Res 2011;4:655-65.
6. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011;378:2081-7.
7. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
8. Baron JA, Sandler RS, Bresalier RS, Lanas A, Morton DG, Riddell R, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet 2008;372:1756-64.
9. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
10. Solomon SD, McMurray JJ, PfefferMA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
11. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011; 124:426-33.
12. Morse MA, Nair SK, Mosca PJ, Hobeika AC, Clay TM, Deng Y, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003;21:341-9.
13. Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12(3 Pt 1): 869-77.
14. Harrop R, Connolly N, Redchenko I, Valle J, Saunders M, Ryan MG, et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial. Clin Cancer Res 2006;12(11 Pt 1):3416-24.
15. Burgdorf SK, Fischer A, Myschetzky PS, Munksgaard SB, Zocca MB, Claesson MH, et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol Rep 2008;20:1305-11.
16. Sakakibara M, Kanto T, Hayakawa M, Kuroda S, Miyatake H, Itose I, et al. Comprehensive immunological analyses of colorectal cancer patients in the phase I/II study of quickly matured dendritic cell vaccine pulsed with carcinoembryonic antigen peptide. Cancer Immunol Immunother 2011;60:1565-75.
17. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
18. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.
19. http://www.ncbi.nlm.nih.gov/gds.
20. http://www.ebi.ac.uk/arrayexpress/.
21. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYCdriven cancer. Proc Natl Acad Sci 2012;109:9545-50.
22. Wu Y, Connors D, Barber L, Jayachandra S, Hanumegowda UM, Adams SP. Multiplexed assay panel of cytotoxicity in HK-2 cells for detection of renal proximal tubule injury potential of compounds. Toxicol In Vitro 2009;23:1170-8.
23. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 2001;7:185-91.
24. Goodell V, McNeel D, Disis ML. His-tag ELISA for the detection of humoral tumor-specific immunity. BMC Immunol 2008;9:23-25.
25. http://www.ncbi.nlm.nih.gov/pubmed/.
26. William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009;8:213-25.
27. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 2009;35:201-9.
28. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002;21:4120-8.
29. Kim JC, KimDD, Lee YM, Kim TW, Cho DH, KimMB, et al. Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 2009;24:209-18.
30. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 2001;61:3124-30.
31. Kita H, Hikichi Y, Hikami K, Tsuneyama K, Cui ZG, Osawa H, et al. Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis. J Gastroenterol 2006;41:1053-63.
32. Dai YC, Zhu XS, Nan QZ, Chen ZX, Xie JP, Fu YK, et al. Identification of differential gene expressions in colorectal cancer and polyp by cDNA microarray. World J Gastroenterol 2012;18:570-5.
33. Sena P, Mariani F, Marzona L, Benincasa M, Ponz de Leon M, Palumbo C, et al. Matrix metalloproteinases 15 and 19 are stromal regulators of colorectal cancer development from the early stages. Int J Oncol 2012;41:260-6.
34. Wang W, Zhu W, Xu XY, Nie XC, Yang X, Xing YN, et al. The clinicopathological significance of REIC expression in colorectal carcinomas. Histol Histopathol 2012;27:735-43.
35. Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, et al. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246.
36. Sun L, Hu H, Peng L, Zhou Z, Zhao X, Pan J, et al. P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer. Am J Pathol 2011;179:380-90.
37. Horiuchi S, Yamamoto H, Min Y, Adachi Y, Itoh F, Imai K. Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol 2003;200:568-76.
38. Sun Y, Yokoi K, Li H, Gao J, Hu L, Liu B, et al. NGAL expression is elevated in both colorectal adenoma-carcinoma sequence and cancer progression and enhances tumorigenesis in xenograft mouse models. Clin Cancer Res 2011;17:4331-40.
39. Fang YJ, Ju ZH, Wang F, Wu XJ, Li LR, Zhang LY, et al. Prognostic impact of ERb and MMP7 expression on overall survival in colon cancer. Tumour Biol 2010;31:651-8.
40. Mollevi DG, Aytes A, Padulles L, Martinez-Iniesta M, Baixeras N, Salazar R, et al. PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer 2008;99:1718-25.
41. Albasri A, Al-Ghamdi S, Fadhil W, Aleskandarany M, Liao YC, Jackson D, et al. Cten signals through integrin-linked kinase (ILK) and may promote metastasis in colorectal cancer. Oncogene 2011;30:2997-3002.
42. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009;24:875-84.
43. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007;132:127-38.
44. Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res 2007; 67:6531-4.
45. Beatty PL, Narayanan S, Gariepy J, Ranganathan S, Finn OJ. Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res 2010;3:438-46.
46. Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006;24:762-8.
47. Milicic A, Harrison LA, Goodlad RA, Hardy RG, Nicholson AM, Presz M, et al. Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res 2008;68:7760-8.
48. Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, et al. Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 2012;1826:297-311.
49. Liffers ST, Maghnouj A, Munding JB, Jackstadt R, Herbrand U, Schulenborg T, et al. Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3epsilon. BMC Cancer 2011;11:137.
50. Birkenkamp-Demtroder K, Mansilla F, Sorensen FB, Kruhoffer M, Cabezon T, Christensen LL, et al. Phosphoprotein Keratin 23 accumulates in MSS but not MSI colon cancers in vivo and impacts viability and proliferation in vitro. Mol Oncol 2007;1:181-95.
51. Ochiai H, Nakanishi Y, Fukasawa Y, Sato Y, Yoshimura K, Moriya Y, et al. A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology (Williston Park) 2008;75: 32-41.
52. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002;20:2624-32.
53. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001;107:477-84.